Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New diabetes pill shows promise in early human tests

NCT ID NCT00707954

Disease control Sponsor: Tanabe Pharma Corporation Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested an experimental drug called TA-7284 in 61 adults with type 2 diabetes. Participants took different doses (25 to 400 mg) or a placebo once daily for 15 days. The main goal was to check safety and how the drug moves through the body, with a secondary look at its effect on blood sugar and urine glucose.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
TA-7284 (an experimental oral diabetes drug)
What this could lead to
If successful, this could lead to a new daily pill to help control blood sugar in people with type 2 diabetes.
What could go wrong
This is a very early, small study (61 people) focused on safety and dosing, not on proving the drug works. Many drugs fail at this stage.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1/2

Runs two stages together: safety and dose first, then whether the treatment works.

Participants

61 people

The number who actually took part.

Start date

Jun 2008

Finished

Feb 2009

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

25 to 65 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Clinically stable Type 2 Diabetes Mellitus * Females without childbearing potential * Body mass index (BMI) \>= 18.5 kg/m2 and \<= 39.9 kg/m2 * Hemoglobin A1c levels \>= 6.5% and \<= 10% * Fasting blood glucose levels \>= 140 mg/dL and \<= 270 mg/dL * Systolic blood pressure \>= 95 mmHg and \<= 160 mmHg, and diastolic blood pressure \>= 50 mmHg and \<= 100 mmHg, and pulse rate \>= 50 bpm * Patients who have not been administered anti-diabetic medication within 2 weeks Prior to dosing * Medicines if necessary for Hypertension or Dyslipidemia should be administered with stable dosage at least 3 months * Treatment with diet and exercise should be unchanged for more than 3 months Exclusion Criteria: * Type 1 Diabetes Mellitus or Secondary Diabetic Mellitus * History of diabetic complications which need treatment * Treatment with insulin, thiazolidinediones, thiazide diuretics、beta blockers or systemic steroids within 3 months prior to informed consent * Serum creatinine \> upper limit of the normal range * Patients with significant complications

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Type 2 diabetes mellitus are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

diabetes mellitus type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Type 2 diabetes mellitus

Contacts and locations

Locations

  • P-One Clinic

    Hachiōji, Tokyo-to, Japan

More trials for these conditions

Other studies related to the condition(s) this trial covers.